135 related articles for article (PubMed ID: 35367753)
1. Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.
Li X; Dean DC; Yuan J; Temple TH; Trent JC; Rosenberg AE; Yu S; Hornicek FJ; Duan Z
Biomed Pharmacother; 2022 May; 149():112888. PubMed ID: 35367753
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibition suppresses rheumatoid arthritis inflammation via blockage of NF-κB activation and IL-1β/IL-6 secretion.
Hong H; Zeng Y; Jian W; Li L; Lin L; Mo Y; Liu M; Fang S; Xia Y
J Cell Mol Med; 2018 Feb; 22(2):1292-1301. PubMed ID: 29083085
[TBL] [Abstract][Full Text] [Related]
3. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
4. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
5. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
6. Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells.
Liu WX; Liu XY; Yu H; Chen Y; Hao Q
Mol Med Rep; 2015 Mar; 11(3):1745-51. PubMed ID: 25411854
[TBL] [Abstract][Full Text] [Related]
7. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
[TBL] [Abstract][Full Text] [Related]
8. CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future.
Yuan J; Li X; Yu S
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188680. PubMed ID: 35051528
[TBL] [Abstract][Full Text] [Related]
9. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
10. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
11. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
12. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
13. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
[TBL] [Abstract][Full Text] [Related]
15. CDK7 inhibitors as anticancer drugs.
Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
[TBL] [Abstract][Full Text] [Related]
16. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.
Tamrakar S; Kapasi AJ; Spector DH
J Virol; 2005 Dec; 79(24):15477-93. PubMed ID: 16306619
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
Kelso TW; Baumgart K; Eickhoff J; Albert T; Antrecht C; Lemcke S; Klebl B; Meisterernst M
Mol Cell Biol; 2014 Oct; 34(19):3675-88. PubMed ID: 25047832
[TBL] [Abstract][Full Text] [Related]
20. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
